HGH Frag 176-191
Human Growth Hormone Fragment 176-191 • Also called HGH Fragment 176-191, Frag 176-191, HGH Frag
HGH Frag 176-191 remains a durable search term in fat-loss and physique circles, but we do not currently have a clear FDA category or approved human drug path for it.
Current status
Restricted
Body-composition interest, with current federal compounding constraints still in play.
FDA category
No clear FDA signal
Can pharmacies compound this?
No
Reclassification expected?
Unclear
FDA has publicly described Human Growth Hormone Fragment among unapproved drugs sold for human use, which reinforces the lack of a defensible mainstream pharmacy pathway.
Primary Use
Body-composition interest
Also searched as
HGH Fragment 176-191, Frag 176-191, HGH Frag
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
May 9, 2016
Current status signal recorded: No clear FDA category or approved-drug pathway identified; FDA has publicly noted Human Growth Hormone Fragment among drugs not approved for use in humans..
Get notified...
Get notified when HGH Frag 176-191 status changes
State-specific notes
Texas
Body-composition peptides without a clear federal path remain hard to source compliantly.